Long-Term Lemtrada Study Shows Promise for Controlling Multiple Sclerosis
Sanofi Genzyme, this past Monday (April 18, 2016), presented the results of the 10-year clinical efficacy trial of its multiple sclerosis (MS) drug, Lemtrada, at the 86th American Academy of Neurology 2016 Annual Meeting. Alemtuzumab, marketed under the brand name Lemtrada, treats the symptoms of relapsing-remitting multiple sclerosis (RRMS).
Researchers from the University of Cambridge School of Clinical Medicine tracked patients for a 10-year period. The study found that 76 percent of patients were free from “confirmed disability worsening” for six months. Overall, 78 percent of the patients had a stable or improved expanded disability status scale (EDSS) score. The EDSS is a tool which measures the disability status of patients with MS.
Results of the study also showed that most patients had a low annualized relapse rate throughout the duration of the study. The findings of the study confirm that Lemtrada is a viable long-term treatment for RRMS that provides stability and may also provide an improvement of symptoms.
With the results of the study, the manufacturer is now seeking Lemtrada’s approval as a standard treatment for RRMS. Lemtrada provides excellent results with infrequent need for administering the medication and no need for continuous treatment (the patients in the study only received three courses of Lemtrada over 10 years).
The U.S. Food and Drug Administration approved the use of Lemtrada in November 2014.
Multiple Sclerosis is One of the Main Causes of Disability by Disease
Multiple sclerosis is almost always a qualifying condition for Social Security disability benefits. If you cannot work due to MS symptoms, the Disability Help Group can help. Contact us at 800-800-2009 to schedule a consultation with our disability advocates!